Vanguard Group Inc Champions Oncology, Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Champions Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 327,029 shares of CSBR stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

327,029

Previous 307,874 6.22%

Holding current value

$2.05 Million

Previous $2.67 Million 9.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$5.72 - $8.85 $109,566 - $169,521	19,155 Added 6.22%	327,029 $2.41 Million
Q1 2025 May 09, 2025	BUY	$8.2 - $11.7 $7,150 - $10,202	872 Added 0.28%	307,874 $2.67 Million
Q2 2024 Aug 13, 2024	BUY	$4.5 - $5.23 $996,291 - $1.16 Million	221,398 Added 258.63%	307,002 $1.59 Million
Q1 2024 May 10, 2024	BUY	$4.9 - $6.91 $13,558 - $19,119	2,767 Added 3.34%	85,604 $419,000
Q4 2023 Feb 14, 2024	BUY	$4.56 - $6.59 $64,555 - $93,294	14,157 Added 20.61%	82,837 $465,000
Q3 2023 Nov 14, 2023	BUY	$5.2 - $7.32 $3,499 - $4,926	673 Added 0.99%	68,680 $426,000
Q4 2022 Feb 10, 2023	SELL	$3.75 - $7.69 $1 Million - $2.06 Million	-267,608 Reduced 79.74%	68,007 $306,000
Q3 2022 Nov 14, 2022	SELL	$7.21 - $9.47 $73,743 - $96,859	-10,228 Reduced 2.96%	335,615 $2.52 Million
Q1 2022 May 13, 2022	BUY	$7.26 - $8.53 $19,674 - $23,116	2,710 Added 0.79%	345,843 $2.81 Million
Q4 2021 Feb 14, 2022	BUY	$7.76 - $10.23 $120,256 - $158,534	15,497 Added 4.73%	343,133 $2.87 Million
Q2 2021 Aug 13, 2021	BUY	$8.45 - $11.72 $2.77 Million - $3.84 Million	327,636 New	327,636 $3.37 Million

Others Institutions Holding CSBR

# of Institutions

Shares Held

5.81M

Call Options Held

35.4K

Put Options Held

View Full List

About CHAMPIONS ONCOLOGY, INC.

Ticker CSBR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,522,400
Market Cap $84.7M
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...

More about CSBR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Champions Oncology, Inc. Transaction History